If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Rule 13d-7 for other parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 6 Pages

CUSIP No.  40416E10313DPage 2 of 6 Pages

CUSIP No.  40416E103               13D                        Page 3 of 6 Pages

Explanatory Note

The following constitutes Amendment No. 5 (“Amendment No. 5”) to the Schedule 13D filed by the undersigned on March 4, 2016, as amended by Amendment No. 1 thereto filed March 1, 2018, Amendment No. 2 filed February 8, 2019, Amendment No. 3 filed June 7, 2019 (“Schedule 13D”), and Amendment #4 filed December 13, 2019. Capitalized terms used but not otherwise defined in this Amendment No. 5 shall have the meanings ascribed to such terms in the Schedule 13D. Except as otherwise provided herein, each Item of the Schedule 13D remains unchanged.

Item 3.  Source and Amount of Funds or Other Consideration.

Item 3 of this Schedule 13D is hereby amended to add the following information:

This Amendment No. 5 is being filed to report that, as of February 8, 2021 (the “Report Date”), the Reporting Person is deemed the beneficial owner of an additional 110,000 shares of Common Stock by virtue of stock options that have vested as of the Report Date.  The stock options vested as follows:

- Options to purchase 27,500 shares of Common Stock (“Common Shares”) at an exercise price of $40.00 per share vested on January 7, 2021, pursuant to a Nonqualified Stock Option Agreement dated January 7, 2017 between the Issuer and the Reporting Person.

- Options to purchase 27,500 Common Shares at an exercise price of $40.00 per share vested on February 8, 2021 pursuant to a Nonqualified Stock Option Agreement dated February 8, 2018 between the Issuer and the Reporting Person.

- Options to purchase 27,500 Common Shares at an exercise price of $53.00 per share vested on January 15, 2021 pursuant to a Nonqualified Stock Option Agreement dated January 15, 2019 between the Issuer and the Reporting Person.

- Options to purchase 27,500 Common Shares at an exercise price of $48.00 per share vested on January 16, 2021 pursuant to a Nonqualified Stock Option Agreement dated January 16, 2020 between the Issuer and the Reporting Person.

The grant of the options described in this Item 3 have been previously reported on applicable Form 4s filed with the U.S. Securities and Exchange Commission (“SEC”).

Item 5.  Interest in Securities of the Issuer.

Item 5 of this Schedule 13D is hereby amended and restated as follows:

The ownership percentages set forth herein are based on 8,076,131 shares of Common Stock outstanding as of February 8, 2021 plus 275,000 shares of Common Stock representing the Reporting Person’s vested options to purchase 110,000 shares of Common Stock at an exercise price of $40.00 per share, expiring January 7, 2027; vested options to purchase 82,500 shares of Common Stock at an exercise price of $40.00 per share, expiring February 8, 2028; vested options to purchase 55,000 shares of Common Stock at an exercise price of $53.00 per share, expiring January 15, 2029; and vested options to purchase 27,500 shares of Common Stock at an exercise price of $48.00 per share, expiring January 16, 2030 representing a total of 8,351,131 shares of Common Stock deemed outstanding for purposes of calculating the Reporting Person’s ownership percentages herein.  

(a) As of the date of this Schedule 13D/A, the Reporting Person directly owns (jointly with spouse) 447,000 shares of Common Stock, directly owns (personally) 273,000 shares of Common Stock, and directly owns 60,000 Restricted Shares (all of which the Reporting Person may vote and receive dividends and other distributions but may not assign, sell, transfer, pledge, encumber or otherwise alienate or hypothecate).  The Reporting Person indirectly owns (via his IRA) 35,000 shares of Common Stock.  The Reporting Person beneficially owns 275,000 shares of Common Stock issuable upon exercise of vested options.  The Common Stock beneficially owned by the Reporting Person represents 13.1% of the total number of shares of Common Stock outstanding as of the date of this Schedule 13D/A.

CUSIP No. 40416E103               13D                        Page 4 of 6 Pages

(b) The Reporting Person has and will continue to have the sole power to vote 755,000 shares of Common Stock (447,000 of which such power is jointly held with spouse), 60,000 Restricted Shares, and 275,000 shares of Common Stock if and when the Reporting Person exercises the vested options.  The Reporting Person has the sole power to dispose of 755,000 shares of Common Stock and 275,000 shares of Common Stock if and when the Reporting Person exercises the vested options.  The Reporting Person, upon the vesting of all 60,000 Restricted Shares, will have the sole power to dispose of such 60,000 Restricted Shares, in addition to the Common Stock held directly by him and the shares issuable upon exercise of the vested options as set forth immediately above.

(c) The information set forth in Item 3 above is incorporated by reference into this Item 5(c).

(d) Other than the Reporting Person, no other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Reporting Person’s shares of Common Stock, shares of Common Stock issuable to the Reporting Person upon exercise of the options or Restricted Shares; provided, however, that the Reporting Person may not assign, sell, transfer, pledge, encumber or otherwise alienate or hypothecate any of his 60,000 Restricted Shares until they are vested.

(e) Not applicable.

Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

Item 6 of this Schedule 13D is hereby amended to add the following information:

The summary of the Nonqualified Stock Option Agreements, as set forth in Item 3, is incorporated herein by reference. The foregoing summary of these agreements is generalized, does not purport to be complete and, as such, is qualified in its entirety by the Nonqualified Stock Option Agreements set forth in Exhibits 99.4, 99.6, 99.8, and 99.10 below and incorporated into this Item 6 by reference.

Other than as described in the Schedule 13D filed on March 4, 2016, the Schedule 13D/A filed on March 1, 2018, the Schedule 13D/A filed on February 8, 2019, the Schedule 13D/A filed on June 7, 2019, and the Schedule 13D/A filed on December 13, 2020, there are no contracts, arrangements, understandings or relationships between the Reporting Person and any person with respect to any securities of the Issuer, including, but not limited to, the transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option agreements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

Item 7.  Material to be Filed as Exhibits.

Item 7 of this Schedule 13D is hereby amended and restated as follows:

CUSIP No. 40416E103               13D                        Page 5 of 6 Pages

CUSIP No. 40416E103               13D                        Page 6 of 6 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.